Danone is a French food and beverage company, widely known for its dairy products like Actimel. This company has agreed to acquire Huel, a UK-based producer of meal replacements for health conscious consumers, for €1 billion. The bid is quite high given Huel’s £250 million reported revenue for 2025.

Huel’s main consumer base constitutes young professionals that are seeking convenient and nutritionally complete meals. The increase in people using weight-loss drugs like Ozempic and young individuals who are becoming more health-conscious is driving demand for the business.

Analysis

This acquisition neatly reflects the overarching trends that are reshaping the food industry: younger consumers have less time, weight-loss medications are becoming more popular, and there is increasing demand for foods that offer health benefits beyond basic sustenance.

Huel’s own quick growth trajectory in becoming a €1 billion acquisition target is demonstrative of how successful targeting niche consumer segments that are willing to pay a premium can be. Recently, drugs like Ozempic and Wegovy are particularly benefitting Huel’s business model, as these drugs dramatically suppress people’s appetite in ways which makes it difficult for them to consume adequate nutrition without careful meal planning. Huel covers this planning with its pre-made meals.

What does this development mean for the food sector?

• Startups and venture investors focused on consumer health brands face strong exit pathways as larger companies like Danone seek to acquire growth opportunities rather than develop them organically.

• Ultra-processed foods of the sort Huel produces, while being marketed as healthy alternatives, face scrutiny from critics and regulators that threaten serious reputational risk.

• Weight-loss medication is creating substantial opportunity for food companies that offer compatible nutritional products.